InsidersTradesSigma
Follow the Quanterix Corp share price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Quanterix Corp has logged 364 reports. Market capitalisation: €147.6m. The latest transaction was disclosed on 20 August 2026 (Levée d'options). Among the most active insiders: Toloue Masoud. All data is free.
364
Insider Decl.
n/a
Thresholds
€7m
15 ops.
Buy Volume
€3m
86 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Quanterix Corp Hold (neutral), based on 3 analysts. Average price target: US$3.00.
31Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,932 of 28,958 companies
13.4
score / 100
Value2
Quality24
FCF yld-64%
Earn yld-86%
EV/EBITDA·
ROE-46%
Gross mgn47%
Net mgn-77%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 August 2026
Declarations364 total
3,955 sharesCommon StockSEC:0001689757-26-000005:0
2,802 sharesCommon StockSEC:0001207928-26-000009:0
25 shares@ US$2.590.0001% mcap1.3% of flowCommon StockSEC:0002120516-26-000015:1
41 shares@ US$2.590.0001% mcap2.1% of flowCommon StockSEC:0002120516-26-000015:3
41 shares@ US$2.590.0001% mcap2.1% of flowCommon StockSEC:0002120516-26-000015:5
111 shares@ US$2.590.0002% mcap5.7% of flowCommon StockSEC:0002120516-26-000015:7
834 sharesCommon StockSEC:0002120516-26-000015:8
249 shares@ US$2.590.0005% mcap12.8% of flowCommon StockSEC:0002120516-26-000015:9
81 sharesCommon StockSEC:0002120516-26-000015:0
136 sharesCommon StockSEC:0002120516-26-000015:2
135 sharesCommon StockSEC:0002120516-26-000015:4
372 sharesCommon StockSEC:0002120516-26-000015:6
72,245 shares@ US$2.930.15% mcap14.5% of flowCommon StockSEC:0001207928-26-000008:1
Canonical exit: 11 Nov 2026 (T+90)
27,155 shares@ US$2.750.054% mcap5.1% of flowCommon StockSEC:0001207928-26-000008:0
Canonical exit: 10 Nov 2026 (T+90)
130 sharesCommon StockSEC:0002120516-26-000014:0
39 shares@ US$3.480.0001% mcap3.6% of flowCommon StockSEC:0002120516-26-000014:1
81 sharesCommon StockSEC:0002120516-26-000013:0
25 shares@ US$4.240.0001% mcap2.7% of flowCommon StockSEC:0002120516-26-000013:1
41 shares@ US$4.240.0001% mcap4.4% of flowCommon StockSEC:0002120516-26-000013:3
41 shares@ US$4.240.0001% mcap4.4% of flowCommon StockSEC:0002120516-26-000013:5
135 sharesCommon StockSEC:0002120516-26-000013:4
136 sharesCommon StockSEC:0002120516-26-000013:2
372 sharesCommon StockSEC:0002120516-26-000013:6
834 sharesCommon StockSEC:0002120516-26-000013:8
111 shares@ US$4.240.0003% mcap11.9% of flowCommon StockSEC:0002120516-26-000013:7
25 of 364 declarations
About Quanterix Corp
Quanterix Corp. (NASDAQ: QTRX) is a U.S.-based life sciences company headquartered in Billerica, Massachusetts, United States. For international investors, the company sits at the intersection of biomarker science, diagnostics, and translational research. Founded in 2007, Quanterix built its franchise around its proprietary Simoa® platform, which is designed to detect and quantify proteins at extremely low concentrations in blood, serum, plasma, and other biofluids. That ultra-sensitivity is the core of its investment case and the basis of its differentiation versus more conventional measurement technologies. ([quanterix.com](https://www.quanterix.com/about-us/)) Quanterix’s business model is centered on instruments, consumables, assay kits, and related services. Its customer base spans academic research institutions, reference laboratories, biopharma companies, and diagnostic developers. The company’s products include Simoa analyzers and assay kits used in biomarker discovery, clinical research, and emerging diagnostic workflows. Management presents Quanterix as a “discovery-to-diagnostics” platform, with a particularly strong footprint in neurodegenerative disease research, where sensitive biomarker detection is critical for Alzheimer’s and related conditions. ([ir.quanterix.com](https://ir.quanterix.com/news-releases/news-release-details/quanterix-expands-reach-ivd-and-large-reference-labs)) From a competitive standpoint, Quanterix is a specialized technology leader rather than a broad-based diagnostics conglomerate. Its moat comes from technical sensitivity, a meaningful installed base, and a large scientific validation record. The company states that its technology has been supported by more than 3,400 peer-reviewed publications, which helps reinforce credibility in the research community. Geographically, Quanterix sells directly in North America and several European countries, while also reaching customers globally through distribution partners. ([ir.quanterix.com](https://ir.quanterix.com/news-releases/news-release-details/quanterix-releases-financial-results-second-quarter-2025)) A key recent strategic development is the 2025 acquisition of Akoya Biosciences, which expanded Quanterix into spatial biology and multiplex tissue imaging with single-cell resolution. The combined platform is intended to connect blood-based and tissue-based biology, broadening Quanterix’s addressable opportunities in neurology, immunology, and oncology. In 2025, the company also highlighted regulatory and commercial progress in markets such as China and South Korea, as well as new collaborations supporting Alzheimer’s testing infrastructure. ([ir.quanterix.com](https://ir.quanterix.com/news-releases/news-release-details/quanterix-launches-novel-p-tau-205-and-p-tau-212-assays-advance?utm_source=openai)) For investors, Quanterix remains a specialized growth story listed on the NASDAQ in the United States, with exposure to research funding cycles and pharmaceutical spending, but with a differentiated platform positioned for precision medicine applications. ([ir.quanterix.com](https://ir.quanterix.com/news-releases/news-release-details/quanterix-releases-financial-results-first-quarter-2025?utm_source=openai))
